Case report · 10 Aug 2026
Conference abstractPublished 2 Jun 2025
Does use of statins aggravate glycemic control in patients with type 2 diabetes: A retrospective cohort study
Addis Ababa University, Ethiopia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: The main purpose of the study was to assess glycemic control among statin users versus non-users in type 2 diabetes patients for a nine-year follow-up period. Method: A retrospective cohort study was used on 204 study subjects in Tikur Anbesa specialized hospital. medical records of eligible patients were followed from January 1, 2011 until the occurrence of the outcome, date of administrative censoring or April 24, 2019. Result: The mean fasting blood glucose of statin users and non-statin users were 176.2 mg/dL (standard error of mean [SEM]: 2.9 mg/dL) and 163.9 (SEM: 3.1 mg/dL, respectively. The Kaplan- Meier analysis showed that non-statin users had a better glycemic control than patients who were taking statins at all levels of time (Log Rank Chi-Square=19.1, p < 0.001). Besides this, after propensity score matching, there was a statistically significant difference in mean FBG time between statin users and non-statin users (t202 = 2.901, p<0.004). Concerning the predictors, there were statistically significant difference for glycemic control for ages ranging 50 to 54 years (adjusted hazard ratio [AHR] =0.401; 95% CI [confidence interval]: 0.195–0.823), metformin 1000 mg (AHR=0.410; 95% CI: 0.243–0.693) and simvastatin 40 mg (AHR=0.396; 95% CI: 0.229–0.686) compared to their corresponding controls (75 to 79 years and the absence of the medications, respectively). Conclusion: This study provides a benchmark for assessing the association of statins with poor glycemic control at the comprehensive specialized hospital. Moving forward, we call for the health care providers to closely monitor the glycemic control of diabetic patients taking statins and place a special effort in optimizing the treatment outcome. Keywords: Stain users, non-statin users, dyslipidemia, glycemic control, cohort
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Trials.
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ephrem Tesfay”
